An announcement from oVRcome:

We’re excited to share some important updates about the oVRcome Clinician Portal, based on your feedback and what we’ve learned during our beta phase.

The Clinician Portal is now free to use for the remainder of 2025.

This includes full access to both in-clinic (MetaQuest) and remote (smartphone) exposures. We’ve removed the separate subscription types to simplify things—one account, full access, unlimited clients, no confusion.

Why the change?

Over the past seven months, we’ve learned a lot from clinicians like you. You’ve helped shape the platform, and we’re now confident that simplifying access and accelerating clinician adoption is the right next step.

We want to:

  • Remove barriers to access while we build broader institutional support.
  • Simplify our pricing model by unifying all use cases into one subscription.
  • Learn even more to improve the platform with your ongoing feedback.

What happens after 2025?

To be transparent: in 2026, we’ll introduce two tiers:

  • Free (Lite) version (suitable for most clinics)
  • Premium version—no more than US$49/month per clinician

What do you need to do?

Nothing at all. All your client subscriptions will be canceled, and there will be no associated charges for using oVRcome until the end of the year. All client smartphone accounts will remain active with full access.

We have not communicated directly with clients using (or paying for) the smartphone subscription, so if any of your clients use this service, feel free to share the good news with them.

Our goal is to build a truly world-class platform that supports scalable, evidence-based exposure therapy.

In 2026, when we launch our two-tier model—a free (Lite) version and a Premium version—as a thank-you for being an early adopter, you will be guaranteed access to the Premium version for no more than US$49/month per clinician—a fraction of what comparable platforms cost. You can also remain on the Lite version at no cost; the choice will be yours. This will include unlimited smartphone subscriptions but will exclude any hardware or shipping costs.

This approach lets us grow responsibly, gather meaningful insights, and ensure the product continues to meet the real-world needs of clinicians and clients alike.

If you have any questions at all about these changes, please do not hesitate to get in touch.

If you have questions or ideas or would like to be involved in future research, reach out to Adam Hutchinson, CEO.